Prevalence and prenatal diagnosis of congenital malformations in the Parisian population: Twenty years of surveillance by the Paris Registry of congenital malformations;Prévalence et diagnostic prénatal des malformations en population Parisienne: Vingt ans de surveillance par le Registre des malformations congénitales de Paris

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 34, Issue 1, 2005, Pages 8-16

  De Vigan, C ^a   Khoshnood, B ^a   Lhomme, A ^a   Vodovar, V ^a   Goujard, J ^a   Goffinet, F ^a  

^a INSERM   (France)

Author keywords

Malformations; Pregnancy termination; Prenatal screening; Prevalence; Registry

Indexed keywords

ANENCEPHALUS; ANORECTAL MALFORMATION; ARTICLE; CHROMOSOME ABERRATION; CONGENITAL DIAPHRAGM HERNIA; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; DISEASE CLASSIFICATION; ESOPHAGUS ATRESIA; FALLOT TETRALOGY; FETUS; FETUS MALFORMATION; GREAT VESSELS TRANSPOSITION; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; INTESTINE ATRESIA; KIDNEY AGENESIS; MAJOR CLINICAL STUDY; NERVOUS SYSTEM MALFORMATION; OMPHALOCELE; PREGNANCY TERMINATION; PRENATAL DIAGNOSIS; PREVALENCE; SCREENING TEST; SPINA BIFIDA; TRISOMY 13; TRISOMY 18; TRISOMY 21; TURNER SYNDROME;

EID: 13244249847     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0368-2315(05)82665-1     Document Type: Article

References (33)

1. Hatton F, Bouvier-Colle MH, Blondel B, Pequignot F, Letoullec A. Trends in infant mortality in France: frequency and causes from 1950 to 1997. Arch Pediatr 2000; 7: 489-500.
2. Trends in infant mortality attributable to birth defects-United States, 1980-1995. MMWR Morb Mortal Wkly Rep 1998; 47: 773-8.
3. Lee K, Khoshnood B, Chen L, Wall SN, Cromie WJ, Mittendorf RL. Infant mortality from congenital malformations in the United States, 1970-1997. Obstet Gynecol 2001; 98: 620-7.
4. Liu S, Joseph KS, Kramer MS, Allen AC, Sauve R, Rusen ID et al. Relationship of prenatal diagnosis and pregnancy termination to overall infant mortality in Canada. JAMA 2002; 287: 1561-7.
5. Economic costs of birth defects and cerebral palsy-United States, 1992. MMWR Morb Mortal Wkly Rep 1995; 44: 694-9.
6. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999; 341: 461-7.
7. Nicolaides KH, Heath V, Cicero S. Increased fetal nuchal translucency at 11-14 weeks. Prenat Diagn 2002; 22: 308-15.
8. Ayme S, Morichon N, Goujard J, Nisand I. Prenatal diagnosis in France. Eur J Hum Genet 1997; 5 (suppl 1): 26-31.
9. Stoll C, Dott B, Alembik Y, Roth MP. Evaluation of routine prenatal diagnosis by a registry of congenital anomalies. Prenat Diagn 1995; 15: 791-800.
10. Grandjean H, Larroque D, Levi S. The performance of routine ultrasonographic screening of pregnancies in the Eurofetus Study. Am J Obstet Gynecol 1999; 181: 446-54.
11. De Vigan C, Vodovar V, Verite V, Dehe S, Goujard J. Current French practices for prenatal diagnosis of trisomy 21: a population-based study in Paris, 1992-97. Prenat Diagn 1999; 19: 1113-8.
12. Audibert F, Dommergues M, Benattar C, Taieb J, Champagne C, Frydman R. Dépistage de la Trisomie 21: clarté nucale et/ou marqueurs sériques? Gynecol Obstet Fertil 2001; 29: 599-604.
13. Müller F, Forestier F, Dingeon B and the ABA Study Group. Second trimester trisomy 21 maternal serum marker screenning. Results of a countrywide study of 854,902 patients. Prenat Diagn 2002; 22: 925-9.
14. er trimestre de la grossesse (étude Echo PAPP-A.78). J Gynecol Obstet Biol Reprod 2004; 33 (suppl 1): 1S61-6.
15. Julian-Reynier C, Macquart-Moulin G, Aurran Y, Chabal F, Aymé S. Prenatal diagnosis: perceptions of women concerning their pregnancies. J Gynecol Obstet Biol Reprod 1994; 23: 691-5.
16. Seror V, Costet N, Ayme S. Prenatal screening for trisomy 21 with maternal serum markers: information for decision-making in pregnant women. J Gynecol Obstet Biol Reprod 2000; 29: 492-500.
17. Khoshnood B, Blondel B, De Vigan C, Breart G. Socioeconomic barriers to informed decisionmaking regarding maternal serum screening for down syndrome: results of the French National Perinatal Survey of 1998. Am J Public Health 2004; 94: 484-91.
18. De Vigan C, Goujard J, Vodovar V, Uzan S. Management of the fetus with a correctable malformation in Paris maternity units: evolution 1985-1994. Fetal Diagn Ther 1997; 12: 216-20.
19. Bonnet D, Coltri A, Butera G, Fermont L, Le Bidois J, Kachaner J et al. Detection of transposition of the great arteries in fetuses reduces neonatal morbidity and mortality. Circulation 1999; 99: 916-8.
20. De Vigan C, Lemaire I, Vodovar V, Khoshnood B, Goujard J, Goffinet F. Le Registre des malformations congénitales de Paris: surveillance épidémiologique et diagnostic prénatal des malformations: évolution sur vingt ans, 1981-2000. Registre des malformations congénitales, Paris, 2003.
21. e révision de la Classification International Des Maladies). The British Paediatrics Association, London, 1979, p. 1-220.
22. CIM10. Classification statistique international des maladies et des problèmes de santé connexes. Dixième révision. Eds Organisation Mondiale de la Santé, Genève 1993.
23. EUROCAT Report 8: Surveillance of Congenital Anomalies in Europe, 1980-1999. Eds: a EUROCAT Working Group, 2002, Newtownabbey, University of Ulster, Northern Ireland.
24. International Clearinghouse for Birth Defects Monitoring Systems. Annual Report 2002 with data for 2000. Eds: International Center for Birth Defects, Rome 2002.
25. Ayme S. Value of registries in decision making in public health: the example of trisomy 21. Rev Epidemiol Sante Publique 1996; 44 (suppl 1): S82-S89.
26. Cordier S, Bergeret A, Goujard J, Ha MC, Aymé S, Bianchi F et al. Congenital malformations and maternal occupational exposure to glycol ethers. Epidemiology 1997; 8: 355-63.
27. Goujard J. Clusters of birth defects: emergency and management. A review of some publications. Europ J Epidemiol 1999; 15: 853-62.
28. Dolk H, Nichols R and a EUROCAT Working Group. Evaluation of the impact of Chernobyl on the prevalence of congenital anomalies in 16 regions of Europe. Int J Epidemiol 1999; 28: 941-8.
29. Arpino C, Brescianini S, Robert E, Castilla E, Cocchi G, Cornel MC et al. Teratogenic effects of antiepileptic drugs: Uses of an international database on malformations and drug exposure (MADRE). Epilepsia 2000; 41: 1436-43.
30. De Vigan C, Baena N, Cariati E, Clementi M, Stoll C. Contribution of ultrasonographic examination to the prenatal detection of chromosomal abnormalities in 19 centres across Europe. Ann Genet 2001; 44: 209-17.
31. Khoshnood B, De Vigan C, Vodovar V, Goujard J, Goffinet F. A population-based evaluation of the impact of antenatal screening for Down's syndrome in France, 1981-2000. BJOG 2004; 111: 485-90.
32. Khoshnood B, De Vigan C, Vodovar V, Goujard J, Lhomme A, Bonnet D et al. Trends in prenatal diagnosis, pregnancy termination and perinatal mortality of newborns with congenital heart disease in France, 1983-2000: a population-based evaluation. Pediatrics 2004, (sous presse).
33. De Vigan C, Vérité V, Vodovar V, Goujard J. Dix ans d'interruptions médicales de grossesse pour malformations dans la population parisienne, données du registre des malformations congénitales de Paris, 1990-1999. In: Interruption de grossesse pour pathologie fœtale. Eds: V Mirlesse. Médecine-Sciences, Flammarion, 2002, p. 16-21.